Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
- Details
- Category: Novo Nordisk
Embark Biotech ApS and Novo Nordisk A/S have entered into a research collaboration focusing on the discovery of novel treatments for obesity and its associated metabolic pathologies through mechanisms that increase energy expenditure.
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
- Details
- Category: Sanofi
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis.
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
- Details
- Category: Novartis
Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline. Today Novartis holds an R&D and investor update in London which will provide deeper insights into the pipeline including the below.
Amgen Foundation deepens commitment to aspiring scientists worldwide by expanding Amgen Scholars Program
- Details
- Category: Amgen
The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-year, $21 million commitment brings the program to a total of 24 elite institutions across the U.S., Europe, Asia and, for the first time, Australia and Canada.
Boehringer Ingelheim inaugurates new centre for agile working methods
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site. The sustainably built and innovative building was handed over to its future users at an internal ceremony.
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
- Details
- Category: AstraZeneca
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
More Pharma News ...
- Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
- Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
- AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
- Alcon to develop SMART Suite digital health platform for cataract surgery
- FDA approves asthma indication for Dupixent® (dupilumab)
- Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies
- US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer